Last reviewed · How we verify

NCT07172542

High Risk of Death or Disability in Brain Hemorrhage: Role of Spot Sign and Secondary Markers

Not yet recruiting Last updated 15 September 2025
What this trial tests

trial in Intracerebral Hemorrhage in 50 participants. Not yet recruiting.

Timeline
15 October 2025
Primary endpoint
15 May 2026
15 May 2026

Quick facts

Lead sponsorCentre Hospitalier de Gonesse
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment50
Start date15 October 2025
Primary completion15 May 2026
Estimated completion15 May 2026
Sites1 location across France

Conditions studied

Sponsor

Centre Hospitalier de Gonesse

Who can join

18 and older, any sex, with Intracerebral Hemorrhage or Cerebral Hemorrhage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study looks at patients with brain hemorrhage to see if a special sign on brain scans, called the "Spot Sign," combined with other scan features, can predict a higher risk of death or disability. By comparing patient outcomes with existing prediction scores, the study aims to understand whether these scan markers provide extra value in identifying patients at higher risk.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Intracerebral Hemorrhage

Currently open trials in the same condition.

Other Centre Hospitalier de Gonesse trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07172542.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing